New Alzheimer’s drug may be approved soon

A new Alzheimer’s drug may slow the disease’s progress. The good news? It may be on the market sooner rather than later.

A new medication may be showing hopeful results in treating Alzheimer’s disease.

New Alzheimer’s drug may be on the horizon

Lecanemab, a monoclonal antibody treatment for mild cognitive impairment due to Alzheimer’s disease from Eisai Co. Ltd. and Biogen, dissolves or prevents beta-amyloid plaque from forming inside the brain, particularly in the early stages of buildup. In July 2022, it was accepted for accelerated approval by the U.S. Food and Drug Administration. Results from the Clarity AD Phase 3 clinical study showed those on treatment of lecanemab (10 milligrams per kilogram) via biweekly IV infusion, showed a 27% slowing in disease progression at 18 months treatment.

“Alzheimer’s disease is a serious disease that causes significant disability and burden to the people living with Alzheimer’s disease and their families. Treatment options for Alzheimer’s disease are limited and creation of new treatment options is strongly encouraged. Eisai employees have spent time with people living with Alzheimer’s disease to truly understand their feelings and challenges and have been working to create new treatments for many years,” said Haruo Naito, CEO at Eisai.

Learn more

The Norton Neuroscience Institute Memory Center provides evaluation and care for patients with symptoms of memory loss.

With the largest team of board-certified and fellowship-trained specialists in the Louisville and Southern Indiana region, our team helps patients and their loved ones find the causes of memory issues, dementia and other brain disorders.

Scientists believe buildup of plaque in the brain could be responsible for damaging and killing nerve cells. Most researchers believe plaques somehow play a critical role in blocking communication among nerve cells and disrupting processes cells need to survive.

While research continues on lecanemab and its potential to help Alzheimer’s patients, Gregory E. Cooper, M.D., Ph.D., neurologist and medical director of Norton Neuroscience Institute Memory Center, said the initial results seem promising.

“There are only a handful of drugs approved to manage the symptoms of Alzheimer’s, but none treat the cause,” Dr. Cooper said. “This drug may slow the buildup of the plaques that cause Alzheimer’s. Considering how devastating this disease is for patients and their families, it’s exciting to see new, potential advancements on the horizon.”

According to the Alzheimer’s Association, more than 6 million Americans are living with the disease. It’s one of the top 10 leading causes of death in the U.S., and the fifth leading cause of death among adults ages 65 or older.

Schedule an Appointment

Select an appointment date and time from available spots listed below.